Symbols / RNTX Stock $1.73 -5.80% Rein Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
RNTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. James Brian Windsor Ph.D.
Exch · Country NCM · United States
Market Cap 48.60M
Enterprise Value 93.38M
Income -49.87M
Sales —
FCF (ttm) -11.37M
Book/sh -1.02
Cash/sh 0.12
Employees 10
Insider 10d —
IPO Jun 29, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B -1.70
P/C —
EV/EBITDA -4.26
EV/Sales —
Quick Ratio 0.52
Current Ratio 0.70
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.96
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-26
Earnings (prior) 2026-03-26
ROA -31.75%
ROE -139.87%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 28.04M
Shs Float 21.45M
Insider Own 0.07%
Instit Own 38.65%
Short Float 1.74%
Short Ratio 5.39
Short Interest 487.16K
52W High 2.40
vs 52W High -27.78%
52W Low 1.02
vs 52W Low 69.92%
Beta 1.40
Impl. Vol. —
Rel Volume 0.56
Avg Volume 106.10K
Volume 59.45K
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 1
Recom None
Prev Close $1.84
Price $1.73
Change -5.80%
About

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.73
Latest analyst target
3. DCF / Fair value
$-7.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.73
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-21 down Brookline Capital Buy → Hold —
2025-09-22 init HC Wainwright & Co. — → Buy $10
2025-08-19 down Brookline Capital Buy → Hold —
News
RSS: Latest RNTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 VOSS CAPITAL, L.P. Beneficial Owner of more than 10% of a Class of Security — 104,183 $1.22 $127,593
2025-10-28 VOSS CAPITAL, L.P. Beneficial Owner of more than 10% of a Class of Security — 306,050 $1.37 $423,466
2025-10-28 VOSS CAPITAL, LP Beneficial Owner of more than 10% of a Class of Security — 306,050 $1.37 $423,466
2024-12-05 WINDSOR JAMES BRIAN Chief Executive Officer — 400 $2.24 $898
2024-06-17 UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT Beneficial Owner of more than 10% of a Class of Security — 6,607 $3.25 $21,568
2024-06-12 UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT Beneficial Owner of more than 10% of a Class of Security — 24,671 $3.25 $80,710
2024-06-07 UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT Beneficial Owner of more than 10% of a Class of Security — 12,315 $3.25 $40,528
2024-05-01 UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT Beneficial Owner of more than 10% of a Class of Security — 31,151 $4.10 $139,103
2024-05-01 UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT Beneficial Owner of more than 10% of a Class of Security — 20,315 $4.10 $85,473
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
21.93
-21.99%
28.11
+83.16%
15.35
-44.49%
27.65
Research And Development
11.03
-22.59%
14.25
+257.00%
3.99
-77.79%
17.97
Selling General And Administration
10.90
-21.36%
13.86
+22.07%
11.36
+17.32%
9.68
General And Administrative Expense
10.90
-21.36%
13.86
+22.07%
11.36
+17.32%
9.68
Salaries And Wages
3.75
-31.42%
5.46
+100.70%
2.72
-11.25%
3.07
Other Gand A
7.15
-14.82%
8.40
-2.72%
8.63
+30.58%
6.61
Total Expenses
21.93
-21.99%
28.11
+83.16%
15.35
-44.49%
27.65
Operating Income
-21.93
+21.99%
-28.11
-83.16%
-15.35
+44.49%
-27.65
Total Operating Income As Reported
-50.63
+22.24%
-65.11
-300.05%
-16.28
+41.13%
-27.65
EBITDA
-21.93
+21.82%
-28.05
-84.18%
-15.23
+44.58%
-27.48
Normalized EBITDA
6.77
-24.37%
8.95
+161.73%
-14.50
+47.23%
-27.48
Reconciled Depreciation
0.00
-98.41%
0.06
-47.06%
0.12
-29.59%
0.17
EBIT
-21.93
+21.99%
-28.11
-83.16%
-15.35
+44.49%
-27.65
Total Unusual Items
-28.70
+22.43%
-37.00
-4982.42%
-0.73
0.00
Total Unusual Items Excluding Goodwill
-28.70
+22.43%
-37.00
-4982.42%
-0.73
0.00
Special Income Charges
-28.70
+22.43%
-37.00
-3887.07%
-0.93
0.00
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
28.70
-22.43%
37.00
0.00
—
Restructuring And Mergern Acquisition
—
0.00
-100.00%
0.93
0.00
Net Income
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Pretax Income
-50.58
+21.49%
-64.43
-310.99%
-15.68
+42.64%
-27.33
Net Non Operating Interest Income Expense
—
0.40
+0.00%
0.40
+33.33%
0.30
Net Interest Income
—
0.40
+0.00%
0.40
+33.33%
0.30
Interest Income Non Operating
—
0.40
+0.00%
0.40
+33.33%
0.30
Interest Income
—
0.40
+0.00%
0.40
+33.33%
0.30
Other Income Expense
-28.65
+21.10%
-36.31
-4888.32%
-0.73
-328.93%
0.32
Other Non Operating Income Expenses
0.05
-92.99%
0.69
—
0.32
Gain On Sale Of Security
—
0.30
+50.00%
0.20
—
Tax Provision
-0.71
+53.89%
-1.54
0.00
—
Tax Rate For Calcs
0.00
-41.26%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.40
+54.44%
-0.89
0.00
0.00
Net Income Including Noncontrolling Interests
-49.87
+20.69%
-62.88
-301.14%
-15.68
+42.64%
-27.33
Net Income From Continuing Operation Net Minority Interest
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Net Income From Continuing And Discontinued Operation
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Net Income Continuous Operations
-49.87
+20.69%
-62.88
-301.14%
-15.68
+42.64%
-27.33
Normalized Income
-21.57
+19.41%
-26.77
-78.42%
-15.00
+45.10%
-27.33
Net Income Common Stockholders
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Diluted EPS
-1.96
+44.16%
-3.51
-2.63%
-3.42
+43.19%
-6.02
Basic EPS
-1.96
+44.16%
-3.51
-2.63%
-3.42
+43.19%
-6.02
Basic Average Shares
25.44
+41.84%
17.94
+290.09%
4.60
+1.31%
4.54
Diluted Average Shares
25.44
+41.84%
17.94
+290.09%
4.60
+1.31%
4.54
Diluted NI Availto Com Stockholders
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Gain On Sale Of PPE
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
106.01
Current Assets
18.27
Cash Cash Equivalents And Short Term Investments
17.31
Cash And Cash Equivalents
17.31
Cash Equivalents
10.32
Cash Financial
6.99
Other Short Term Investments
0.00
Prepaid Assets
0.21
Restricted Cash
0.03
Other Current Assets
0.72
Total Non Current Assets
87.74
Net PPE
0.02
Gross PPE
0.38
Accumulated Depreciation
-0.36
Properties
0.00
Buildings And Improvements
0.00
Machinery Furniture Equipment
0.38
Other Properties
—
Goodwill And Other Intangible Assets
85.53
Goodwill
6.33
Other Intangible Assets
79.20
Non Current Prepaid Assets
2.14
Other Non Current Assets
0.05
Total Liabilities Net Minority Interest
99.12
Current Liabilities
4.38
Payables And Accrued Expenses
4.13
Payables
1.19
Accounts Payable
1.19
Current Accrued Expenses
2.94
Current Debt And Capital Lease Obligation
0.05
Current Capital Lease Obligation
0.05
Other Current Liabilities
0.21
Total Non Current Liabilities Net Minority Interest
94.74
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Non Current Deferred Liabilities
3.33
Non Current Deferred Taxes Liabilities
3.33
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
91.41
Stockholders Equity
6.89
Common Stock Equity
6.89
Capital Stock
0.09
Common Stock
0.09
Preferred Stock
—
Share Issued
4.89
Ordinary Shares Number
4.89
Treasury Shares Number
0.00
Additional Paid In Capital
295.38
Retained Earnings
-288.52
Gains Losses Not Affecting Retained Earnings
-0.06
Other Equity Adjustments
-0.06
Total Equity Gross Minority Interest
6.89
Total Capitalization
6.89
Working Capital
13.88
Invested Capital
6.89
Total Debt
0.05
Capital Lease Obligations
0.05
Net Tangible Assets
-78.64
Tangible Book Value
-78.64
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-19.36
+13.14%
-22.29
-12.54%
-19.81
+20.34%
-24.86
Cash Flow From Continuing Operating Activities
-19.36
+13.14%
-22.29
-12.54%
-19.81
+20.34%
-24.86
Net Income From Continuing Operations
-49.87
+20.69%
-62.88
-299.71%
-15.73
+42.43%
-27.33
Depreciation Amortization Depletion
0.00
-98.41%
0.06
-47.06%
0.12
-29.59%
0.17
Depreciation And Amortization
0.00
-98.41%
0.06
-47.06%
0.12
-29.59%
0.17
Other Non Cash Items
0.45
—
—
—
Stock Based Compensation
2.22
+99.10%
1.12
-6.13%
1.19
-42.87%
2.08
Asset Impairment Charge
28.70
-22.43%
37.00
0.00
—
Operating Gains Losses
—
—
-0.04
—
Gain Loss On Sale Of PPE
—
0.00
+100.00%
-0.04
0.00
Change In Working Capital
-0.86
-135.86%
2.41
+144.82%
-5.38
-1381.19%
0.42
Change In Prepaid Assets
-0.32
-338.06%
0.13
+162.75%
0.05
-96.84%
1.61
Change In Payables And Accrued Expense
0.44
-68.63%
1.41
+126.32%
-5.36
-404.14%
-1.06
Change In Accrued Expense
-2.62
-255.06%
1.69
+542.67%
-0.38
+75.73%
-1.57
Change In Payable
3.06
+1198.57%
-0.28
+94.40%
-4.98
-1076.86%
0.51
Change In Account Payable
3.06
+1198.57%
-0.28
+94.40%
-4.98
-1076.86%
0.51
Change In Other Working Capital
-0.71
+54.18%
-1.55
—
—
Change In Other Current Assets
0.00
-100.00%
2.19
+73133.33%
-0.00
0.00
Change In Other Current Liabilities
-0.28
-220.96%
0.23
+452.31%
-0.07
+49.61%
-0.13
Investing Cash Flow
—
0.00
-100.00%
16.20
-38.79%
26.46
Cash Flow From Continuing Investing Activities
—
0.00
-100.00%
16.20
-38.79%
26.46
Net PPE Purchase And Sale
—
0.00
-100.00%
0.04
0.00
Purchase Of PPE
—
—
—
0.00
Sale Of PPE
—
0.00
-100.00%
0.04
0.00
Capital Expenditure
—
—
—
—
Net Investment Purchase And Sale
—
0.00
-100.00%
16.25
-38.58%
26.46
Purchase Of Investment
—
—
0.00
+100.00%
-21.85
Sale Of Investment
—
0.00
-100.00%
16.25
-66.36%
48.31
Net Business Purchase And Sale
—
0.00
+100.00%
-0.10
0.00
Purchase Of Business
—
0.00
+100.00%
-0.10
0.00
Financing Cash Flow
9.76
-45.25%
17.82
+12.81%
15.79
0.00
Cash Flow From Continuing Financing Activities
9.76
-45.25%
17.82
+12.81%
15.79
0.00
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
3.41
-67.93%
10.64
0.00
0.00
Proceeds From Stock Option Exercised
3.49
-51.33%
7.17
0.00
0.00
Net Other Financing Charges
2.85
—
15.79
—
Changes In Cash
-9.61
-114.76%
-4.47
-136.72%
12.18
+664.24%
1.59
Effect Of Exchange Rate Changes
-0.04
0.00
+100.00%
-0.06
0.00
Beginning Cash Position
12.87
-25.80%
17.34
+232.21%
5.22
+43.97%
3.62
End Cash Position
3.21
-75.01%
12.87
-25.80%
17.34
+232.21%
5.22
Free Cash Flow
-19.36
+13.14%
-22.29
-12.54%
-19.81
+20.34%
-24.86
Amortization Of Securities
—
0.00
-100.00%
0.03
+115.38%
-0.21
Common Stock Issuance
3.41
-67.93%
10.64
0.00
0.00
Issuance Of Capital Stock
3.41
-67.93%
10.64
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category